|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chemotherapy-induced GSTO1 expression in breast cancer cells leads to chemoresistance and promotes metastasis.
|
30873742 |
2019 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of GSTO1 A140D and GSTO2 N142D Gene Variations with Breast Cancer Risk
|
28670895 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in GSTM1, GSTP1, and GSTO1 enzymes increase the risk of developing breast cancer and hepatocellular carcinoma.
|
26682223 |
2015 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis demonstrates that GSTO2 polymorphism may significantly increase cancer risk in Caucasian population and is associated with elevated risk of breast cancer; while GSTO1 polymorphism is not associated with cancer risk.
|
25300926 |
2014 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ΔPK induces calpain activation in both melanoma and breast cancer 3D cultures as determined by the loss of the p28 regulatory subunit, and 3D growth is restored by treatment with the calpain inhibitor PD150606.
|
24553345 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our results indicated that the peptide p28 (VLCSIDWFM) could serve as a novel candidate epitope for the development of peptide vaccines against PLAC1-positive breast cancer.
|
21710262 |
2012 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of the study suggest that GSTO1 and GSTO2 variants are not associated with breast cancer risk, but that wild-type GSTO1 (A140/A140) is likely among cases at an advanced stage.
|
20210239 |
2010 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case-control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status.
|
19859803 |
2010 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No association between GSTA1 polymorphism and breast cancer was found whereas carriers of the GSTO1 *B/*B genotype had higher risks of breast cancer when compared with carriers of the GSTO1 *A/*A genotype (incidence rate ratio 1.62, 95% confidence interval: 1.01-2.61).
|
18414193 |
2008 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study suggests that GSTO1*A140D polymorphism could play an important role as a risk factor for the development of hepatocellular carcinoma, cholangiocarcinoma and breast cancer.
|
15992993 |
2006 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The top 20 differentially expressed genes included 10 genes (Spp1, Cyp1b1, Btg1, Cfh, Mt1, Mt2, Igfbp5, Gstm1, Gstm2, and Esr1) implicated in various aspects of ovarian carcinomas, and other 3 genes (Gsto1, Lcn7, and Alcam) associated to breast cancer.
|
16245302 |
2006 |